Product Information
IBANDRONATE 3 MG/3 ML SYRINGE is a generic product labeled by Eugia US LLC, priced at $52.6478 per ML under NDC 55150019183. Its NADAC has been published 98 times since Nov 20, 2024.
FDA first approved this application on Aug 19, 2015. Its Orange Book therapeutic-equivalence code is AP.
Strength
3 mg/3mL
Manufacturer
Eugia US LLCNDC
55150019183
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
IBANDRONATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA205332FDA Approved
8/19/2015
TE Code
AP
On Market Since
8/19/2015
Pharmacological Classes
Price Statistics
The NADAC for IBANDRONATE 3 MG/3 ML SYRINGE has been published 98 times since Nov 20, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $52.6478 per ML |
|---|---|
| All-time high | $54.2117 (Sep 16, 2026) |
| All-time low | $49.5953 (Oct 22, 2025) |
| 52-week high | $54.2117 |
| 52-week low | $49.5953 |
| Median price | $53.3244 |
| Average price | $53.1162 |
| Largest weekly change | -7.0% (Oct 22, 2025) |
| Weeks tracked | 98 |
| Tracking since | Nov 20, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Ibandronate Sodium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eugia US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibandronate Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bisphosphonate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBANDRONATE 3 MG/3 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for IBANDRONATE 3 MG/3 ML SYRINGE, manufactured by Eugia US LLC, is $52.6478 per ML (NDC 55150019183), effective Sep 30, 2026.
How has the price of IBANDRONATE 3 MG/3 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for IBANDRONATE 3 MG/3 ML SYRINGE has held within roughly two percent of its current level. It has been tracked across 98 weekly CMS publications since Nov 20, 2024.
What are the highest and lowest recorded NADAC prices for IBANDRONATE 3 MG/3 ML SYRINGE?
Since Nov 20, 2024, the NADAC for IBANDRONATE 3 MG/3 ML SYRINGE has ranged from a low of $49.5953 (Oct 22, 2025) to a high of $54.2117 (Sep 16, 2026), with a median of $53.3244 per ML.
Are there cheaper alternatives to IBANDRONATE 3 MG/3 ML SYRINGE?
No other NADAC-published product currently shares the active ingredient and strength of IBANDRONATE 3 MG/3 ML SYRINGE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures IBANDRONATE 3 MG/3 ML SYRINGE?
IBANDRONATE 3 MG/3 ML SYRINGE (NDC 55150019183) is labeled by Eugia US LLC, and CMS classifies it as a generic product.